Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials

References

• Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561–1573.
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359(21):2254–2265.
   PubMed Web of Science ®Google Scholar
• Matte A, Cappellini MD, Iolascon A, et al. Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment? Expert Opin Investig Drugs. 2020;29(1):23–31.
   PubMed Web of Science ®Google Scholar
• Howard J, Ataga KI, Brown RC, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8(5):e323–e33.
   PubMedGoogle Scholar
• Telen MJ. Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events? Blood Adv. 2020;4(14):3457–3465.
   PubMed Web of Science ®Google Scholar
• Boye-Doe A, Brown E, Puri-Sharma C, et al. The grndad registry: contemporary natural history data and an analysis of Real-World patterns of use and limitations of disease modifying therapy in adults with SCD. Blood. 2020;136(Supplement 1):34–36.
   Google Scholar
• Simpson S. Sickle cell disease: a new era. Lancet Haematol. 2019;6(8):e393–e4.
   PubMed Web of Science ®Google Scholar
• Grosse SD, Schechter MS, Kulkarni R, et al. Models of comprehensive multidisciplinary care for individuals in the United States with genetic disorders. Pediatrics. 2009;123(1):407–412.
   PubMed Web of Science ®Google Scholar
• Kanter J, Falcon C. Gene therapy for sickle cell disease: where we are now? Hematology. 2021;2021(1):174–180.
   PubMedGoogle Scholar
• Quach D, Jiao B, Basu A, et al. A landscape analysis and discussion of value of gene therapies for sickle cell disease. Expert Rev Pharmacoecon Outcomes Res. 2022;1–21. DOI:10.1080/14737167.2022.2060823.
   PubMed Web of Science ®Google Scholar
• Payne AB, Mehal JM, Chapman C, et al. Trends in sickle cell Disease-Related mortality in the United States, 1979 to 2017. Ann Emerg Med. 2020;76(3s):S28–s36.
   PubMedGoogle Scholar
• Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519.
   PubMed Web of Science ®Google Scholar
• Ashorobi D, Bhatt R. Bone marrow transplantation in sickle cell disease. 2019.
   Google Scholar
• Singh PC, Ballas SK. Emerging drugs for sickle cell anemia. Expert Opin Emerg Drugs. 2015;20(1):47–61.
   PubMed Web of Science ®Google Scholar
• Yanni E, Grosse SD, Yang Q, et al. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr. 2009;154(4):541–545.
   PubMed Web of Science ®Google Scholar
• Chou ST, Alsawas M, Fasano RM, et al. American society of hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327–355.
   PubMed Web of Science ®Google Scholar
• Uter S, An HH, Linder GE, et al. Measures to reduce red cell use in patients with sickle cell disease requiring red cell exchange during a blood shortage. Blood Adv. 2021;5(12):2586–2592.
   PubMed Web of Science ®Google Scholar
• Coates TD, Wood JC. How we manage iron overload in sickle cell patients. Br J Haematol. 2017;177(5):703–716.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010;85(6):403–408.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010;115(12):2354–2363.
   PubMed Web of Science ®Google Scholar
• Hariri E, Mansour A, El Alam A, et al. Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment. Int Urol Nephrol. 2018;50(6):1075–1083.
   PubMed Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia—TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670.
   PubMed Web of Science ®Google Scholar
• McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749–1758.
   PubMed Web of Science ®Google Scholar
• Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300–5311.
   PubMed Web of Science ®Google Scholar
• Conran N, Torres L. cGMP modulation therapeutics for sickle cell disease. Exp Biol Med (Maywood). 2019;244(2):132–146.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312(10):1033–1048.
   PubMed Web of Science ®Google Scholar
• Kotiah SD, Ballas SK. Investigational drugs in sickle cell anemia. Expert Opin Investig Drugs. 2009;18(12):1817–1828.
   PubMed Web of Science ®Google Scholar
• Walters MC, De Castro LM, Sullivan KM, et al. Indications and results of HLA-Identical sibling hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2016;22(2):207–211.
   PubMed Web of Science ®Google Scholar
• Frangoul H, Bobruff Y, Cappellini MD, et al. Safety and efficacy of CTX001 in patients with transfusion-dependent β-thalassemia and sickle cell disease: early results from the climb THAL-111 and climb SCD-121 studies of autologous CRISPR-CAS9-modified CD34+ hematopoietic stem and progenitor cells. Blood. 2020;136:3–4.
   PubMed Web of Science ®Google Scholar
• Ribeil J-A, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848–855.
   PubMed Web of Science ®Google Scholar
• Jones RJ, DeBaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood. 2021;138(11):942–947.
   PubMed Web of Science ®Google Scholar
• Huo J, Xiao H, Garg M, et al. The economic burden of sickle cell disease in the United States. Value Health. 2018;21:S108.
   Google Scholar
• Carden MA, Little J. Emerging disease-modifying therapies for sickle cell disease. Haematologica. 2019;104(9):1710–1719.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Desai PC. Advances in new drug therapies for the management of sickle cell disease. Expert Opin Orphan Drugs. 2018;6(5):329–343.
   PubMed Web of Science ®Google Scholar
• Telen MJ, Malik P, Vercellotti GM. Therapeutic strategies for sickle cell disease: towards a multi-agent approach. Nat Rev Drug Discov. 2019;18(2):139–158.
   PubMed Web of Science ®Google Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439.
   PubMed Web of Science ®Google Scholar
• Tampaki A, Gavriilaki E, Varelas C, et al. Complement in sickle cell disease and targeted therapy: i know one thing, that I know nothing. Blood Rev. 2021;48:100805.
   PubMed Web of Science ®Google Scholar
• Casella JF, Barton BA, Kanter J, et al. Effect of Poloxamer 188 vs placebo on painful Vaso-Occlusive episodes in children and adults with sickle cell disease: a randomized clinical trial. Jama. 2021;325(15):1513–1523.
   PubMed Web of Science ®Google Scholar
• Vona R, Sposi NM, Mattia L, et al. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
   Web of Science ®Google Scholar
• Mack AK, Kato GJ. Sickle cell disease and nitric oxide: a paradigm shift? Int J Biochem Cell Biol. 2006;38(8):1237–1243.
   PubMed Web of Science ®Google Scholar
• Kaddam L, Fadl-Elmula I, Eisawi OA, et al. Gum Arabic as novel anti-oxidant agent in sickle cell anemia, phase II trial. BMC Hematol. 2017;17(1):1–6.
   PubMedGoogle Scholar
• Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 1990;40:63–279.
   PubMedGoogle Scholar
• Esrick EB, McConkey M, Lin K, et al. Inactivation of HDAC 1 or HDAC 2 induces gamma globin expression without altering cell cycle or proliferation. Am J Hematol. 2015;90(7):624–628.
   PubMed Web of Science ®Google Scholar
• Steinberg MH. Fetal hemoglobin in sickle cell anemia. Blood. 2020;136(21):2392–2400.
   PubMed Web of Science ®Google Scholar
• Vissa M, Vichinsky E. Voxelotor for the treatment of sickle cell disease. Expert Rev Hematol. 2021;14(3):253–262.
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Gordeuk VR, Telfer P, et al. Higher hemoglobin levels achieved with voxelotor are associated with lower vaso-occlusive crisis incidence: 72-week analysis from the HOPE study. Blood. 2020;136:31–32.
   Web of Science ®Google Scholar
• Shah N, Lipato T, and Alvarez O, et al. Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis. Expert Rev Hematol. 2022;15(2):167–173.
   PubMed Web of Science ®Google Scholar
• Brown RCC, Redfern A, Lisbon E, et al. GBT021601, a next generation HbS polymerization inhibitor: results of safety, tolerability, pharmacokinetics and pharmacodynamics in adults living with sickle cell disease and healthy volunteers. Blood. 2021;138:3099.
   Google Scholar
• Rab MA, Bos J, van Oirschot BA, et al. Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy. Blood J Am Soc Hematol. 2021;137(21):2997–3001.
   Google Scholar
• Schroeder P, Fulzele K, Forsyth S, et al. Etavopivat, a pyruvate kinase activator in red blood cells, for the treatment of sickle cell disease. J Pharmacol Exp Ther. 2022;380(3):210–219.
   PubMed Web of Science ®Google Scholar
• Xu JZ, Conrey A, Frey I, et al. Mitapivat (AG-348) demonstrates safety, tolerability, and improvements in anemia, hemolysis, oxygen affinity, and hemoglobin S polymerization kinetics in adults with sickle cell disease: a phase 1 dose escalation study. Blood. 2021;138:10.
   Google Scholar
• Ikuta T, Ausenda S, Cappellini MD. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase–cGMP-dependent protein kinase pathway. Proc Nat Acad Sci. 2001;98(4):1847–1852.
   PubMed Web of Science ®Google Scholar
• Head CA, Swerdlow P, McDade WA, et al. Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis. Am J Hematol. 2010;85(10):800–802.
   PubMed Web of Science ®Google Scholar
• Weiner DL, Hibberd PL, Betit P, et al. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. Jama. 2003;289(9):1136–1142.
   PubMed Web of Science ®Google Scholar
• Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. Jama. 2011;305(9):893–902.
   PubMed Web of Science ®Google Scholar
• Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013;98(9):1375.
   PubMed Web of Science ®Google Scholar
• Miyashiro J, Pant A, Tchernychev B, et al. The effect of the soluble guanylyl cyclase stimulator olinciguat on ƴ-globin gene induction in K562 cells. Blood. 2018;132:1078.
   Web of Science ®Google Scholar
• Potoka KP, Gladwin MT. Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2015;308(4):L314–L24.
   PubMed Web of Science ®Google Scholar
• Potoka KP, Wood KC, Baust JJ, et al. Nitric oxide–independent soluble guanylate cyclase activation improves vascular function and cardiac remodeling in sickle cell disease. Am J Respir Cell Mol Biol. 2018;58(5):636–647.
   PubMed Web of Science ®Google Scholar
• Andemariam B, Mant T, Eleftheriou P, et al. Treatment with IMR-687, a highly selective PDE9 inhibitor, increases HbF and reduces VOCs in adults with sickle cell disease in a Long-Term, phase 2a, Open-Label extension study. Blood. 2021;138:2046.
   Google Scholar
• Manwani D. P-selectin and sickle cell disease: a balancing act. Blood J Am Soc Hematol. 2021;137(19):2573–2574.
   Google Scholar
• Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015;125(17):2656–2664.
   PubMed Web of Science ®Google Scholar
• Dampier CD, Telen MJ, Wun T, et al. Early initiation of treatment with rivipansel for acute vaso-occlusive crisis in sickle cell disease (SCD) achieves earlier discontinuation of IV opioids and shorter hospital stay: reset clinical trial analysis. Blood. 2020;136:18–19.
   Web of Science ®Google Scholar
• Biemond BJ, Tombak A, Kilinc Y, et al. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021;8(5):e334–e43.
   PubMed Web of Science ®Google Scholar
• Han J, Saraf SL, Gordeuk VR. Systematic review of crizanlizumab: a new parenteral option to reduce Vaso-occlusive pain crises in patients with sickle cell disease. Pharmacotherapy. 2020;40(6):535–543.
   PubMed Web of Science ®Google Scholar
• Mayer C, Cooper DS, Redfern A, et al. Preliminary results of a phase 1 study in healthy subjects administered inclacumab, a fully human IgG4 Anti-P-Selectin monoclonal antibody in development for treatment of sickle cell disease. Blood. 2021;138:977.
   PubMedGoogle Scholar
• Telen MJ. Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease. Blood J Am Soc Hematol. 2016;127(7):810–819.
   Google Scholar
• Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. Jama. 2001;286(17):2099–2106.
   PubMed Web of Science ®Google Scholar
• Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost. 2007;98(2):392–396.
   PubMed Web of Science ®Google Scholar
• Heeney MM, Hoppe CC, Abboud MR, et al. A multinational trial of prasugrel for sickle cell vaso-occlusive events. N Engl J Med. 2016;374(7):625–635.
   PubMed Web of Science ®Google Scholar
• Kanter J, Abboud MR, Kaya B, et al. Ticagrelor does not impact patient‐reported pain in young adults with sickle cell disease: a multicentre, randomised phase II b study. Br J Haematol. 2019;184(2):269–278.
   PubMed Web of Science ®Google Scholar
• Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013;6(1):1–10.
   PubMedGoogle Scholar
• Quinn CT. l-Glutamine for sickle cell anemia: more questions than answers. Blood J Am Soc Hematol. 2018;132(7):689–693.
   Google Scholar
• Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235.
   PubMed Web of Science ®Google Scholar
• Niihara Y, Macan H, Eckman J, et al. L-Glutamine therapy reduces hospitalization for sickle cell anemia and sickle β°-thalassemia patients at six months–a phase II randomized trial. Clin Pharmacol Biopharm. 2014;3(116):2.
   Google Scholar
• Heyland D, Muscedere J, Wischmeyer PE, et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med. 2013;368(16):1489–1497.
   PubMed Web of Science ®Google Scholar
• Nur E, Brandjes DP, Teerlink T, et al. N-acetylcysteine reduces oxidative stress in sickle cell patients. Ann Hematol. 2012;91(7):1097–1105.
   PubMed Web of Science ®Google Scholar
• Sins JW, Fijnvandraat K, Rijneveld AW, et al. N-acetylcysteine in patients with sickle cell disease: a randomized controlled trial. Blood. 2016;128(22):123.
   Web of Science ®Google Scholar
• Lal A, Suh J, Atamna W, et al. Anti-Oxidant treatment with α-Lipoic acid and Acetyl L-Carnitine in hemoglobinopathies. Blood. 2007;110(11):3799.
   Web of Science ®Google Scholar
• Bao B, Prasad AS, Beck FW, et al. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. Transl Res. 2008;152(2):67–80.
   PubMed Web of Science ®Google Scholar
• Rees DC, Kilinc Y, Unal S, et al. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood J Am Soc Hematol. 2022;139(17):2642–2652.
   Google Scholar
• Glassberg J, Minnitti C, Cromwell C, et al. Inhaled steroids reduce pain and sVCAM levels in individuals with sickle cell disease: a triple‐blind, randomized trial. Am J Hematol. 2017;92(7):622–631.
   PubMed Web of Science ®Google Scholar
• Lim SH, Dutta D, Moore J. Rifaximin for sickle cell disease. Am J Hematol. 2019;94(12):E325–E8.
   PubMed Web of Science ®Google Scholar
• Lim SH, Morris A, Li K, et al. Intestinal microbiome analysis revealed dysbiosis in sickle cell disease. Am J Hematol. 2018;93(4):E91–E3.
   PubMed Web of Science ®Google Scholar
• Bartolucci P, Ataga K, Callaghan M, et al. P119: trial in progress: the randomized, double-blind, placebo-controlled phase 1B CROSSWALK-A trial evaluating the safety of Crovalimab for the management of acute uncomplicated vaso-occlusive episodes (VOES) in patients (PTS) with sickle cell disease (SCD). HemaSphere. 2022;6(Suppl):27.
   Google Scholar
• Thomas AM, Gerogianni A, McAdam MB, et al. Complement component C5 and TLR molecule CD14 mediate heme-induced thromboinflammation in human blood. J Immunol. 2019;203(6):1571–1578.
   PubMed Web of Science ®Google Scholar
• Darbari DS, Wang Z, Kwak M, et al. Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PloS one. 2013;8(11):e79923.
   PubMed Web of Science ®Google Scholar
• Shah N, Bhor M, Xie L, et al. Evaluation of vaso-occlusive crises in United States sickle cell disease patients: a retrospective claims-based study. J Health Econ Outcomes Res. 2019;6(3):106.
   PubMedGoogle Scholar
• Glaros AK, Razvi R, Shah N, et al. Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor. Ther Adv Hematol. 2021;12:20406207211001136.
   Web of Science ®Google Scholar
• Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood J Am Soc Hematol. 2011;118(4):855–864.
   Google Scholar
• Lee LH, Whisenton LH, Benger J, et al. A community-centered approach to sickle cell disease and clinical trial participation: an evaluation of perceptions, facilitators, and barriers. Blood Adv. 2021;5(23):5323–5331.
   PubMed Web of Science ®Google Scholar
• Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa. N Engl J Med. 2019;380(2):121–131.
   PubMed Web of Science ®Google Scholar
• Pecker LH, Lanzkron S. Sickle cell disease. Ann Intern Med. 2021;174(1):ITC1–ITC16.
   PubMed Web of Science ®Google Scholar
• Gualandro SFM, Fonseca GH, Yokomizo IK, et al. Cohort study of adult patients with haemoglobin SC disease: clinical characteristics and predictors of mortality. Br J Haematol. 2015;171(4):631–637.
   PubMed Web of Science ®Google Scholar
• Luchtman-Jones L, Pressel S, Hilliard L, et al. Effects of hydroxyurea treatment for patients with hemoglobin SC disease. Am J Hematol. 2016;91(2):238–242.
   PubMed Web of Science ®Google Scholar
• Pecker LH, Schaefer BA, Luchtman‐Jones L. Knowledge insufficient: the management of haemoglobin SC disease. Br J Haematol. 2017;176(4):515–526.
   PubMed Web of Science ®Google Scholar
• Mnika K, Pule GD, Dandara C, et al. An expert review of pharmacogenomics of sickle cell disease therapeutics: not yet ready for global precision medicine. OMICS. 2016;20(10):565–574.
   PubMed Web of Science ®Google Scholar
• Investigators OPSPiSCAT. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769–2778.
   PubMed Web of Science ®Google Scholar